10-K
Annual Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
26 line items · 2 periods
XBRL
| Item | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 3,750,525 | 2,827,082 |
Prepaid expenses and other current assets | 308,239 | 371,597 |
Total Current Assets | 4,058,764 | 3,198,679 |
Equity Method Investments | 1,676,591 | — |
Intangible assets, net | 3,348 | 3,913 |
Equity method investment | 981,830 | 1,534,013 |
Equity Method Investments | 981,830 | 1,534,013 |
Total Assets | 5,043,942 | 4,736,605 |
Current Liabilities: | ||
Accounts payable | 250,130 | 103,325 |
Related Party | 48,272 | 24,062 |
Accrued expenses | 677,456 | 477,747 |
Related Party | — | 47,942 |
Total Current Liabilities | 975,858 | 653,076 |
Equity Method Investments | 537,303 | — |
Total Liabilities | 975,858 | 653,076 |
Stockholders’ Equity | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 6,474,588 and 1,663,421 shares issued and outstanding at December 31, 2024 and 2023, respectively | 6,473 | 1,663 |
Additional paid in capital | 86,056,934 | 72,879,738 |
Accumulated deficit | (81,995,323) | (68,797,872) |
Total Stockholders’ Equity | 4,068,084 | 4,083,529 |
Common Stock | 6,473 | 1,663 |
Additional Paid In Capital | 86,056,934 | 72,879,738 |
Accumulated Deficit | (81,995,323) | (68,797,872) |
Total Liabilities and Stockholders’ Equity | 5,043,942 | 4,736,605 |